# US 2003/0083265 A1 · TGF-beta inhibitors and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0083265 A1
- Document ID: US20030083265A1
- Status: Published application
- Kind: A1
- Application number: 10/304,586
- Filed: 2002-11-25
- Published: 2003-05-01
- Earliest claimed: 2000-09-29
- Inventors: Rajendra S. Bhatnagar; Craig A. Gough; Jing Jing Qian
- Web page: https://patentgrep.com/patent/US20030083265A1

## CPC

- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/495: Transforming growth factor [TGF]
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A family of small peptides have been found to be inhibitory to TGF-β activity, and preferably have the primary structure of Formula 1: Formula I AA1-AA2-AA3-Pro-D-Glu-Ala wherein AA1 is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine; AA2 is the same or a different amino acid residue as in AA1; and AA3 is alanine or N-methylalanine.

## Claims

### Claim 1

A peptide having the primary structure of Formula I
AA1-AA2-AA3-Pro-D-Glu-Ala Formula I
wherein AA1 is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine; AA2 is the same or a different amino acid residue as in AA1; and AA3 is alanine or N-methylalanine.

### Claim 2

The peptide Leu-Ile-Ala-Pro-D-Glu-Ala.

### Claim 3

The peptide Phe-Ile-Ala-Pro-D-Glu-Ala.

### Claim 4

The peptide Leu-Phe-Ala-Pro-D-Glu-Ala.

### Claim 5

A therapeutic composition, comprising:
AA1-AA2-AA3-Pro-D-Glu-Ala Formula I
wherein AA1 is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine, AA2 is the same or a different amino acid residue as in AA1; and AA3 is alanine or N-methylalanine; and,
a physiologically acceptable carrier.

### Claim 6 (depends on 5)

The composition as in claim 5 wherein the peptide includes Leu-Ile-Ala-Pro-D-Glu-Ala.

### Claim 7 (depends on 5)

The composition as in claim 5 wherein the peptide includes Phe-Ile-Ala-Pro-D-Glu-Ala.

### Claim 8 (depends on 5)

The composition as in claim 5 wherein the peptide includes Leu-Phe-Ala-Pro-D-Glu-Ala.

### Claim 9 (depends on 5)

The composition as in claim 5 wherein the carrier is suitable for topical administration.

### Claim 10

A method of inhibiting TGF-β, comprising:
administering to a patient in need thereof an effective activity-inhibiting amount of a peptide specific against a fibrotic growth factor, the peptide having the primary structure
AA1-AA2-AA3-Pro-D-Glu-Ala Formula I
wherein AA, is leucine, phenylalanine, α-aminoisobutric acid, N-methylalanine, N-methylisoleucine, or isoleucine; AA2 is the same or a different amino acid residue as in AA1; and AA3 is alanine or N-methylalanine.

### Claim 11 (depends on 10)

The method as in claim 10 wherein the peptide is effective in inhibiting TGF β-1.

### Claim 12 (depends on 10)

The method as in claim 10 wherein the peptide includes Leu-Ile-Ala-Pro-D-Glu-Ala.

### Claim 13 (depends on 10)

The method as in claim 10 wherein the peptide includes Phe-Ile-Ala-Pro-D-Glu-Ala.

### Claim 14 (depends on 10)

The method as in claim 10 wherein the peptide includes Leu-Phe-Ala-Pro-D-Glu-Ala.

### Claim 15 (depends on 10)

The method as in claim 10 wherein the administering is topical application.

### Claim 16 (depends on 15)

The method as in claim 15 wherein the peptide is effective to inhibit scar tissue during wound healing.
